ESC 2019 DAPA-HF研究解读:SGLT2抑制剂的跨界演出

ESC2019 DAPA-HF interpretation:Interdisciplinary Performance of SGLT2 inhibitor

SGLT2抑制剂是近年来诞生的新型降糖药物,在糖尿病领域的几项大型临床研究中证实能减少心血管事件,但获益机制并不能完全归结于血糖的控制。近期ESC上公布的DAPA-HF研究(Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure)证实了SGLT2抑制剂对于未患2型糖尿病的射血分数减低的心力衰竭(HFrEF)患者依然可以显著降低心血管死亡和心力衰竭住院风险,这一里程碑式的研究将开启心力衰竭治疗新的时代。

SGLT2 inhibitors have been emerged as new glucose lowering agents in recent years.Several large scale clinical trials revealed that SGLT2 inhibitors could decrease the risk of adverse cardiovascular events,and shed light on potential beneficial mechanism beyond the glucose control.In European Society of Cardiology Conference 2019,DAPA-HF(Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure)study demonstrated a benefit of dapagliflozin to reduce major adverse outcomes in patients with established heart failure with a reduced ejection fraction,regardless of the presence or absence of diabetes.The milestone clinical trial will launch a new era of heart failure therapy.